For research use only. Not for therapeutic Use.
Oglemilast (GRC 3886) is a potent and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 0.5 nM for PDE4D3. Oglemilast inhibits pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo. Oglemilast has the potential for inflammatory airway diseases[1][2][3].
Oglemilast (GRC 3886) has EC50s of 11.4 nM, 4.4 nM for PDE 4B1 and PDE 4D3 reporter cell lines, respectively[3].
| Catalog Number | I004866 |
| CAS Number | 778576-62-8 |
| Synonyms | N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide |
| Molecular Formula | C20H13Cl2F2N3O5S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28) |
| InChIKey | OKFDRAHPFKMAJH-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F |
| Reference | [1]. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol. 2008 Oct;155(3):288-90. [2]. Rabe KF, et al. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67. [3]. Wunder F, et al. Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter celllines. Mol Pharm. 2013 Oct 7;10(10):3697-705. |
